Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Phase 2 Completed 9 enrolled Stanford University

NaSingle-groupOpen-labelTreatment

To evaluate the toxicity and tolerability of this tandem autologous/allogeneic transplant approach for patients with advanced stage multiple myeloma.

Evaluation	Drug	Modality	Dose	Route
Background	Acetaminophen	Small molecule	650 mg	—
Background	Cyclophosphamide	Other / unclassified	4 g	Intravenous
Background	Cyclosporine	Peptide	5 mg/kg	Oral
Background	Diphenhydramine	Unknown	25 mg	—
Background	Diphenhydramine	Unknown	50 mg	—
Background	Hydrocortisone	Other / unclassified	100 mg	Intravenous
Background	Melphalan	Small molecule	200 mg/m2	Intravenous
Background	Methylprednisolone	Other / unclassified	1 mg/kg	Intravenous
Background	Mycophenolate Mofetil	Small molecule	15 mg/kg	Oral
Background	Thymoglobulin	Protein / enzyme biologic	1.5 mg/kg	Intravenous
Background	filgrastim	Protein / enzyme biologic	5 ug/kg	Subcutaneous
Background	filgrastim	Protein / enzyme biologic	10 ug/kg	Subcutaneous
Background	filgrastim	Protein / enzyme biologic	16 ug/kg	Subcutaneous